Leeds is the host city for the 2022, and we are proud to see Lindsay Jarrett competing tomorrow at approximately 10.30 BST. See the timetable https://t.co/rGiDggiwd3 https://t.co/AExcTwMHDo #a1uksupportgroup#alpha1awareness#alpha1antitrypsindefiency
We’re proud to share @samaritanscharity awareness-raising campaign #TalkToUs this July, to remind people that Samaritans are there for anyone struggling to cope, 24 hours a day, 365 days a year
#TalkToUs https://t.co/AExcTwMHDo #alpha1awareness#alpha1uksupport
α1-antitrypsin deficiency is a heterogeneous disease driven by aberrant protease activity in the presence of low α1-AT levels. Understanding mechanisms driving pathological processes in α1-ATD phenotypes could identify novel therapeutic targets. https://t.co/32v5YaElTP
Mereo is pleased to report positive top-line Data from “ASTRAEUS” a Phase 2 trial of alvelestat in AATD. Join us at 10:30 ET for a conference call to discuss the data in more detail. See the press release for full dial-in details https://t.co/JaQVh47VAt
@ScotsKnight2